CytoMed gets Nasdaq minimum bid deficiency notice
CytoMed Therapeutics said Nasdaq notified it that its ordinary shares closed below the minimum bid price for 30 consecutive business days. The company has until April 5, 2027, to regain compliance.
CytoMed Therapeutics said Nasdaq notified it that its ordinary shares closed below the minimum bid price for 30 consecutive business days. The company has until April 5, 2027, to regain compliance.